Is Mondelez Stock Overvalued?
The company behind Oreo, Ritz, LU, Clif Bar, and Tate’s…
Sell
49
NVCR Quote, Financials, Valuation and Earnings
Last price:
$26.94
Seasonality move
:
5.69%
Day range:
$26.13 - $27.47
52-week range:
$11.70 - $34.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.99x
P/B ratio:
8.05x
Volume:
617K
Avg. volume:
1.1M
1-year change:
92.85%
Market cap:
$2.9B
Revenue:
$509.3M
EPS (TTM):
-$1.40
Analysts' Opinion
-
Consensus RatingNovoCure has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $35.83, NovoCure has an estimated upside of 32.91% from its current price of $26.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing -8.11% downside risk from its current price of $26.96.
Fair Value
-
According to the consensus of 5 analysts, NovoCure has 32.91% upside to fair value with a price target of $35.83 per share.
NVCR vs. S&P 500
-
Over the past 5 trading days, NovoCure has underperformed the S&P 500 by -2.97% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NovoCure does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NovoCure has grown year-over-year revenues for 4 quarters straight. In the most recent quarter NovoCure reported revenues of $155.1M.
Earnings Growth
-
NovoCure has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NovoCure reported earnings per share of -$0.28.
Enterprise value:
2.6B
EV / Invested capital:
--
Price / LTM sales:
4.99x
EV / EBIT:
--
EV / Revenue:
4.52x
PEG ratio (5yr expected):
-0.20x
EV / Free cash flow:
-33.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$441.5M
Return On Assets:
-12.81%
Net Income Margin (TTM):
-25.93%
Return On Equity:
-40.75%
Return On Invested Capital:
-15.43%
Operating Margin:
-20.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $542.6M | $504M | $577.7M | $127.3M | $155.1M | |
| Gross Profit | $427M | $379.4M | $441.5M | $95.2M | $119.7M | |
| Operating Income | -$69.9M | -$224.1M | -$158.9M | -$58.2M | -$32.1M | |
| EBITDA | -$63.7M | -$202.2M | -$103.6M | -$55.4M | -$29.6M | |
| Diluted EPS | -$0.77 | -$1.86 | -$1.40 | -$0.46 | -$0.28 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $383.5M | $1.1B | $1.1B | $1B | $1.1B | |
| Total Assets | $431M | $1.1B | $1.2B | $1.1B | $1.2B | |
| Current Liabilities | $95.3M | $124.5M | $141.1M | $157.2M | $735M | |
| Total Liabilities | $124M | $707.3M | $728.8M | $752.6M | $861.2M | |
| Total Equity | $307M | $413.2M | $445.4M | $393.7M | $360.8M | |
| Total Debt | -- | $561.4M | $564.7M | $568M | $654.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $48.9M | -$62.5M | -$37.5M | -$19.3M | $10.4M | |
| Cash From Investing | -$511M | -$42.4M | -$19.5M | $17.3M | $10.2M | |
| Cash From Financing | $15.7M | $17.3M | $89.5M | $1.2M | $100K | |
| Free Cash Flow | $19.7M | -$89.2M | -$78.2M | -$26.6M | -$307K | |
NVCR
Sector
Market Cap
$2.9B
$45.8M
Price % of 52-Week High
78.6%
47.1%
Dividend Yield
0%
0%
Shareholder Yield
-1.25%
-0.75%
1-Year Price Total Return
92.85%
-32.38%
Beta (5-Year)
0.642
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$26.93
200-day SMA
Buy
Level
$19.55
Bollinger Bands (100)
Buy
Level
14.99 - 27.15
Chaikin Money Flow
Sell
Level
-15M
20-day SMA
Sell
Level
$28.97
Relative Strength Index (RSI14)
Sell
Level
46.34
ADX Line
Sell
Level
38.14
Williams %R
Neutral
Level
-73.7303
50-day SMA
Buy
Level
$25.44
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
97M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8176)
Sell
CA Score
(Annual)
Level (-1.7384)
Buy
Beneish M-Score
(Annual)
Level (-3.1996)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.2252)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Stock Forecast FAQ
In the current month, NVCR has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NVCR average analyst price target in the past 3 months is $35.83.
-
Where Will NovoCure Stock Be In 1 Year?
According to analysts, the consensus estimate is that NovoCure share price will rise to $35.83 per share over the next 12 months.
-
What Do Analysts Say About NovoCure?
Analysts are divided on their view about NovoCure share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NovoCure is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is NovoCure's Price Target?
The price target for NovoCure over the next 1-year time period is forecast to be $35.83 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NVCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NovoCure is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NVCR?
You can purchase shares of NovoCure via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NovoCure shares.
-
What Is The NovoCure Share Price Today?
NovoCure was last trading at $26.94 per share. This represents the most recent stock quote for NovoCure. Yesterday, NovoCure closed at $26.96 per share.
-
How To Buy NovoCure Stock Online?
In order to purchase NovoCure stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Morgan Stanley Stock Be in 10 Years?
Morgan Stanley (NYSE:MS) share price has been on a tear,…
Is Philip Morris Stock Overvalued?
If there is one industry that can be termed truly…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 123x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Alerts
Sell
32
FTAI alert for Jan 23
FTAI Aviation [FTAI] is up 18.3% over the past day.
Sell
2
EDU alert for Jan 23
New Oriental Education & Technology Group [EDU] is up 0.11% over the past day.
Buy
51
GH alert for Jan 23
Guardant Health [GH] is up 6.03% over the past day.
